Medicina Regenerativa
Health ministry panel conditionally approves iPS cell products
Reportado por IA Imagem gerada por IA
A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.
Following an expert panel's recommendation last month, Japan's Health, Labor and Welfare Ministry on March 6 conditionally approved two iPS cell-derived regenerative medicines—the world's first commercialized such treatments—for severe heart failure and Parkinson's disease. The products carry conditions and time limits, with pricing and insurance coverage decisions next; sales could begin as early as summer 2026.
Reportado por IA Verificado
Pesquisadores da Universidade Northwestern dizem que desenvolveram um modelo avançado de organoide de medula espinhal humana cultivado em laboratório que reproduz características chave de lesão traumática — como inflamação e cicatrização glial — e que uma terapia experimental de “moléculas dançantes” reduziu tecido semelhante a cicatriz e promoveu o crescimento de fibras nervosas no modelo.